라이프
전체기사 보기
-
POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award
CHENGDU, China, Dec. 31, 2025 -- On December 27, the 2025 Master of Engineering Management (MEM) Industry Mentor Orientation and Appointment Ceremony was held at the Wenshi Building on the Putuo Campus of East China Normal University (ECNU), located at No. 3663 Zhongshan North Road, Putuo District, Shanghai. Qin Xingjiong, founder of LivingPhoenix Regenerative Technology also chairman of the High-Tech & Supply Chain Branch of the China Association of Plastic Surgery, was formally appointed as an industry mentor for master's students. Professor He Jiaxun—PhD supervisor, prof
- 김갑성 기자
- 2025-12-31 17:21
-
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula
BANGKOK, Dec. 31, 2025 -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, combining prebiotics, probiotics, and postbiotics in a single daily dose. The world of health and wellness has been fundamentally transformed by the pivotal role of Probiotics in supporting gut health and overall well-being. Over the past decade, we have witnessed an explosive surge in probiotic-b
- 김갑성 기자
- 2025-12-31 15:46
-
KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices
SEOUL, South Korea, Dec. 31, 2025 -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The global bone graft market is a high-growth medical device sector, driven by steadily increasing usage in orthopedic surgery, spinal procedures, and dental implants. The market is projected to reach approximately USD 6.66 billion by 2032. In particular, human tissue-based products continue to gain market prefere
- 김갑성 기자
- 2025-12-31 12:44
-
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on the Hong Kong stock market in 2025. With an issue price of HK$ 24.05 per share, Insilico Medicine opened at HK$35.00 per share, representing a market capitalization of approximately HK$ 19.51 billion. Qiming Venture Partners is one of Insilico Medicine's most important institutional investors. Qiming Venture Partners led the C
- 김갑성 기자
- 2025-12-31 08:55
-
Entering the New Year, VARON Strengthens Commitment to Dependable Oxygen Support
NEW YORK, Dec. 31, 2025 -- As the new year begins, it offers a meaningful moment to reflect on shared progress and renewed responsibility in respiratory care. Over the past year, VARON has continued to focus on what matters most—reliability, accessibility, and compassion-driven action that supports real people and real needs. A Year Shaped by Reliability and Everyday Care The past year reinforced the growing importance of dependable oxygen therapy solutions. For many individuals and families, access to an oxygen concentrator for home use has become essentia
- 김갑성 기자
- 2025-12-31 07:34
-
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently completed the first patient dosing in China, becoming the world's first IL-11 targeting drug candidate to initiate clinical trials for pathological scarring. This Phase II clinical trial (CTR20254857) aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9
- 김갑성 기자
- 2025-12-30 22:00
-
China's Sleep Technology Pioneer Sleemon Draws Increasing Interest from the Global AI Community
SHAOXING, China, Dec. 30, 2025 -- A long-established household brand in China with a comparatively limited international profile, Sleemon Healthy Sleep Technology Co., Ltd. is gaining attention from the global technology community as it expands its focus on advanced sleep technology solutions. Founded in 1984, Sleemon was the first mattress manufacturer in China to list publicly (SSE: 603008). While the company adopted its current corporate name in recent years, it has long been recognized in the domestic market for its leadership and sustained investment in sleep technology. In
- 김갑성 기자
- 2025-12-30 21:54
-
The "Eastern Wisdom" of Aging: How Taikang's "New Life Insurance" Responds to a Global Challenge?
SHANGHAI, Dec. 30, 2025 -- Under the global background of ageing people, WallstreetCN reported how TaiKang play its wisdom in new-life-insurance. In 2014, journalists from Japan's NHK documented the phenomenon of A Society Without Bonds, portraying how the elderly in an atomized society—devoid of social, familial, or community ties—gradually become isolated and ultimately pass away alone. A decade later, the Japanese drama Two in the Neighborhood (Douban rating 9.3) offers a starkly different narrative. Its two 55-year-old female protagonists no longer treat aging with tragic s
- 김갑성 기자
- 2025-12-30 19:34
-
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
HONG KONG, Dec. 30, 2025 -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising. "With this massively oversubscribed listing we set several world's firsts
- 김갑성 기자
- 2025-12-30 17:00
-
아태지역 사업자 4명 중 3명, "내년 경제 여건 개선 전망"… 허벌라이프 '아시아태평양 건강 및 경제 역량 인식 조사' 결과 발표
홍콩, 2025년 12월 30일 -- 아시아태평양 지역 사업자들은 향후 1년간 자신의 경제 여건이 개선될 것이라는 기대가 높은 것으로 나타났다. 비(非)사업자에 비해 경제와 건강을 스스로 관리할 수 있다는 인식도 뚜렷해, 삶 전반에 대한 자신감과 주도성이 두드러졌다는 분석이다. 건강 및 웰니스 뉴트리션 전문 글로벌 기업 허벌라이프(Herbalife)가 지난 17일 '2025 아시아태평양 건강 및 경제 역량 인식 조사' 결과를 발표했다. 지난 10월 실시된 '2025 아시아태평양 건강 및 경제 역량 인식 조사'는 호주, 홍콩, 인도네시아, 일본, 한국, 말레이시아, 필리핀, 싱가포르, 대만, 태국, 베트남 등 11개 국가에서 사업자 2,245명을 포함해 총 8,505명을 대상으로 진행됐다. 조사에서 '건강 역량'은 '자신의 신체적, 정신적, 정서적 웰빙 향상에 도움이 되는 결정을 내릴 수 있는 능력'으로, '경제 역량'은 '재정적 안정성을 높이는 능력'으로 정의했다. 조사에 따르면 아태 지역 사업자 응답자 가운데 74%는 향후 12개월 이내 경제적 여건이 개선될 것으로 내다보며, 같은 질문에 긍
- 노기식 기자
- 2025-12-30 16:11
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 8대한약물영양의학회 2020년 추계학술대회
- 92021년 대학생기자단 모집
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-01_THU
- 하이얼, 파리 생제르맹과 손잡고 전 세계 사용자에게 챔피언 경험 선사 20:56
- Haier Teams Up with Paris Saint-Germain to Create Champion Experiences for Global Users 14:30
- Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen 12:36
- 홍보 영상 '민항과 함께, 미래를 향한 승리' 공개 - Xinhua Silk Road: 전 세계 온라인 공개 10:49
- iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene 10:00
- OG Tech Debuts 'War Room' Series, Targets Q1 2026 for Global AI Action Center 10:00
- Hecto Media、AI搭載の多言語Kカルチャープラットフォーム「K-snapp」を発表 06:54
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 01일 22시 40분